Obviously, less than 5% of SMA newborns escapes the screening test, i.e., the compound heterozygotes for the deletion/conversion of exon 7 and another type of SMN1 mutation (SNV or deletions in other gene regions), or homozygotes for other types of SMN1 mutations. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.